SNC-80 is an opioidanalgesic compound that selectively activates μ–δ opioid receptor heteromers[1] and is used primarily in scientific research.[2] Discovered in 1994, SNC-80 was a pioneering non-peptide compound regarded as a highly selective agonist for the δ-opioid receptor.[3]
SNC-80 was the first non-peptide compound developed that was regarded as a highly selective agonist for the δ-opioidreceptor.[4]
It has been shown to produce useful analgesic,[5]antidepressant[6] and anxiolytic effects in animal studies,[7][8] but its usefulness is limited by producing convulsions at high doses,[9] and so SNC-80 is not used medically, although it is a useful compound in scientific research.
^Calderon SN, Coop A (2004). "SNC 80 and related delta opioid agonists". Current Pharmaceutical Design. 10 (7): 733–42. doi:10.2174/1381612043453054. PMID15032699.
^Calderon SN, Rothman RB, Porreca F, Flippen-Anderson JL, McNutt RW, Xu H, et al. (July 1994). "Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(alpha R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide delta opioid receptor agonist". Journal of Medicinal Chemistry. 37 (14): 2125–8. doi:10.1021/jm00040a002. PMID8035418.
^Bilsky EJ, Calderon SN, Wang T, Bernstein RN, Davis P, Hruby VJ, et al. (April 1995). "SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist". The Journal of Pharmacology and Experimental Therapeutics. 273 (1): 359–66. PMID7714789.
^Gallantine EL, Meert TF (July 2005). "A comparison of the antinociceptive and adverse effects of the mu-opioid agonist morphine and the delta-opioid agonist SNC80". Basic & Clinical Pharmacology & Toxicology. 97 (1): 39–51. doi:10.1111/j.1742-7843.2005.pto_97107.x. PMID15943758.
